207 related articles for article (PubMed ID: 33230811)
21. Early innate immune responses to bacterial LPS.
Rosadini CV; Kagan JC
Curr Opin Immunol; 2017 Feb; 44():14-19. PubMed ID: 27842237
[TBL] [Abstract][Full Text] [Related]
22. TLR4 Polymorphisms and Expression in Solid Cancers.
Pandey N; Chauhan A; Jain N
Mol Diagn Ther; 2018 Dec; 22(6):683-702. PubMed ID: 30311146
[TBL] [Abstract][Full Text] [Related]
23. Ethanol extract of propolis and its constituent caffeic acid phenethyl ester inhibit breast cancer cells proliferation in inflammatory microenvironment by inhibiting TLR4 signal pathway and inducing apoptosis and autophagy.
Chang H; Wang Y; Yin X; Liu X; Xuan H
BMC Complement Altern Med; 2017 Sep; 17(1):471. PubMed ID: 28950845
[TBL] [Abstract][Full Text] [Related]
24. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors.
Nishiya T; DeFranco AL
J Biol Chem; 2004 Apr; 279(18):19008-17. PubMed ID: 14976215
[TBL] [Abstract][Full Text] [Related]
25. Significance of toll-like receptors 2 and 4 mRNA expression in chronic hepatitis C virus infection.
Shehata MA; Abou El-Enein A; El-Sharnouby GA
Egypt J Immunol; 2006; 13(1):141-52. PubMed ID: 17974158
[TBL] [Abstract][Full Text] [Related]
26. Toll-like receptor 4 stimulation initiates an inflammatory response that decreases cardiomyocyte contractility.
Avlas O; Fallach R; Shainberg A; Porat E; Hochhauser E
Antioxid Redox Signal; 2011 Oct; 15(7):1895-909. PubMed ID: 21126202
[TBL] [Abstract][Full Text] [Related]
27. p62 is Negatively Implicated in the TRAF6-BECN1 Signaling Axis for Autophagy Activation and Cancer Progression by Toll-Like Receptor 4 (TLR4).
Kim MJ; Min Y; Im JS; Son J; Lee JS; Lee KY
Cells; 2020 May; 9(5):. PubMed ID: 32384667
[TBL] [Abstract][Full Text] [Related]
28. Role of the tumor microenvironment in regulating apoptosis and cancer progression.
Yaacoub K; Pedeux R; Tarte K; Guillaudeux T
Cancer Lett; 2016 Aug; 378(2):150-9. PubMed ID: 27224890
[TBL] [Abstract][Full Text] [Related]
29. Drug Targeting Based on a New Concept-Targeting Against TLR4 as an Example.
Maru Y; Tomita T; Deguchi A; Ieguchi K; Takita M; Tsukahara F; Takemura K; Kitao A; Gusovsky F
Endocr Metab Immune Disord Drug Targets; 2015; 15(2):83-7. PubMed ID: 26004773
[TBL] [Abstract][Full Text] [Related]
30. Toll-like receptor 4 inhibition reduces vascular inflammation in spontaneously hypertensive rats.
Bomfim GF; Echem C; Martins CB; Costa TJ; Sartoretto SM; Dos Santos RA; Oliveira MA; Akamine EH; Fortes ZB; Tostes RC; Webb RC; Carvalho MH
Life Sci; 2015 Feb; 122():1-7. PubMed ID: 25498891
[TBL] [Abstract][Full Text] [Related]
31.
Chu M; Zhou M; Jiang C; Chen X; Guo L; Zhang M; Chu Z; Wang Y
Front Immunol; 2018; 9():862. PubMed ID: 29922279
[TBL] [Abstract][Full Text] [Related]
32. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
[TBL] [Abstract][Full Text] [Related]
33. The contribution of miR-122 to the innate immunity by regulating toll-like receptor 4 in hepatoma cells.
Shi L; Zheng X; Fan Y; Yang X; Li A; Qian J
BMC Gastroenterol; 2019 Jul; 19(1):130. PubMed ID: 31340754
[TBL] [Abstract][Full Text] [Related]
34. Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy.
Li TT; Ogino S; Qian ZR
World J Gastroenterol; 2014 Dec; 20(47):17699-708. PubMed ID: 25548469
[TBL] [Abstract][Full Text] [Related]
35. Toll-Like Receptors (TLRs) in the Tumor Microenvironment (TME): A Dragon-Like Weapon in a Non-fantasy Game of Thrones.
Angrini M; Varthaman A; Cremer I
Adv Exp Med Biol; 2020; 1263():145-173. PubMed ID: 32588327
[TBL] [Abstract][Full Text] [Related]
36. The role of toll-like receptor-4 in the development of multi-organ failure following traumatic haemorrhagic shock and resuscitation.
McGhan LJ; Jaroszewski DE
Injury; 2012 Feb; 43(2):129-36. PubMed ID: 21689818
[TBL] [Abstract][Full Text] [Related]
37. Activation of PAR2 or/and TLR4 promotes SW620 cell proliferation and migration via phosphorylation of ERK1/2.
Zhou B; Zhou H; Ling S; Guo D; Yan Y; Zhou F; Wu Y
Oncol Rep; 2011 Feb; 25(2):503-11. PubMed ID: 21152870
[TBL] [Abstract][Full Text] [Related]
38. Toll-Like Receptor 4 and Heat-Shock Protein 70: Is it a New Target Pathway for Diabetic Vasculopathies?
de Oliveira AA; Webb RC; Nunes KP
Curr Drug Targets; 2019; 20(1):51-59. PubMed ID: 30129410
[TBL] [Abstract][Full Text] [Related]
39. Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy.
Mikulandra M; Pavelic J; Glavan TM
Curr Med Chem; 2017; 24(19):2011-2032. PubMed ID: 28322156
[TBL] [Abstract][Full Text] [Related]
40. Angiotensin II-induced hypertension and cardiac hypertrophy are differentially mediated by TLR3- and TLR4-dependent pathways.
Singh MV; Cicha MZ; Nunez S; Meyerholz DK; Chapleau MW; Abboud FM
Am J Physiol Heart Circ Physiol; 2019 May; 316(5):H1027-H1038. PubMed ID: 30793936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
